Design and applications of modified oligonucleotides

Brazilian Journal of Medical and Biological Research

Volumn 36, Issue 2, 2003, Pages 143-151

  Gallo, M ^a   Montserrat, J M ^a,b   Iribarren, A M ^a,c  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b INSTITUTO DE CIENCIAS   (Argentina)

^c UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Antisense; Aptamers; Modified nucleotides; Oligonucleotide libraries; Ribozymes; SELEX method

Indexed keywords

APTAMER; DEOXYRIBOZYME; DNA; NUCLEASE; OLIGONUCLEOTIDE; RIBOZYME; RNA;

BIOTECHNOLOGY; CHEMICAL MODIFICATION; COMBINATORIAL LIBRARY; GENE AMPLIFICATION; HYBRIDIZATION; MOLECULAR BIOLOGY; NUCLEIC ACID PROBE; NUCLEIC ACID STRUCTURE; NUCLEOTIDE TRANSPORT; POLYMERASE CHAIN REACTION; REVIEW;

EID: 0037291210     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2003000200001     Document Type: Review

References (36)

1. Zamenick PC & Stephenson ML (1978). Inhibition of Rous sarcoma virus replication and transformation by a specific oligonucleotide. Proceedings of the National Academy of Sciences, USA, 75: 280-284.
2. Murakira A (2001). Making sense of antisense. Trends in Molecular Medicine, 7: 430-431.
3. Stein CA & Krieg AM (Editors) (1998). Applied Antisense Oligonucleotide Technology. Wiley-Liss Inc., New York, NY, USA.
4. Zelleger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP & Gleave ME (2001). Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2′-methoxy)-ethyl chemistry. Journal of Pharmacology and Experimental Therapeutics, 298: 934-940.
5. Altmann KH, Fabbro D, Dean NM, Geiger BP, Müller M & Nicklin P (1996). Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochemical Society Transactions, 24: 630-637.
6. Luyten I & Herdewijn P (1998). Hybridization properties of base-modified oligonucleotides within the double and triple helix motif. European Journal of Medicinal Chemistry, 33: 515-578.
7. Herdewijn P (2000). Heterocyclic modifications of oligonucleotides and antisense technology. Antisense and Nucleic Acid Drug Development, 10: 297-310.
8. Seeberger PH & Caruthers MH (1998). Modified oligonucleotides as antisense therapeutics. In: Stein CA & Krieg AM (Editors), Applied Antisense Oligonucleotide Technology. Wiley-Liss Inc., New York, NY, USA, 51-72.
9. Freier SM & Altmann KH (1997). The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically modified DNA:RNA duplexes. Nucleic Acids Research, 25: 4429-4443.
10. Guga P, Koziolkiewicz M, Okuszek A & Stec WJ (1998). Oligo(nucleoside phosphorothioate)s. In: Stein CA & Krieg AM (Editors), Applied Antisense Oligonucleotide Technology. Wiley-Liss Inc., New York, NY, USA, 23-50.
11. Srinivasan SK, Tewary HK & Iversen PL (1995). Characterization of binding sites, extent of binding and drug interactions of oligonucleotides with albumin. Antisense Research and Development, 5: 131-139.
12. Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu CY, Lloyd D, Chen JK, Koziolkiewicz M & Calabretta B (1996). Oligonucleotide (N3′→P5′) phosphoramidates as antisense agents. Nucleic Acids Research, 24: 1508-1514.
13. Iribarren AM, Sproat BS, Neuner P, Sulston I, Ryder U & Lamond AI (1990). 2′-O-alkyl oligoribonucleotides as antisense probes. Proceedings of the National Academy of Sciences, USA, 87: 7747-7751.
14. Tereshko V, Portmann S, Tay EC, Martin P, Natt F, Altmann KH & Egli M (1998). Correlating structure and stability of DNA duplexes with incorporated 2′-O-modified RNA analogs. Biochemistry 37: 10626-10634.
15. Agrawal S (1999). Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochimica et Biophysica Acta, 1489: 53-68.
16. Iribarren AM, Cicero DO & Neuner PJ (1994). Resistance to degradation by nucleases of (2′S)-2′-deoxy-2′C-methyloligonucleotides, novel potential antisense probes. Antisense Research and Development, 4: 95-98.
17. Cicero DO, Gallo M, Neuner PJ & Iribarren AM (2001) Synthesis and properties of (2′S)- and (2′R)-2′-deoxy-2′C-methyl oligonucleotides. Tetrahedron, 57: 7613-7621.
18. Schmdt C, Bévierre MO, De Mesmaeker A & Altmann KH (1994). The effects of 2′- and 3′-alkyl substituents on oligonucleotide hybridization and stability. Bioorganic and Medicinal Chemistry Letters, 4: 1969-1974.
19. Manoharan M (1999). 2′-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochimica et Biophysica Acta, 1489: 117-130.
20. Eckstein F & Lilley DMJ (Editors) (1997). Catalytic RNA. Nucleic Acids and Molecular Biology. Vol. 10. Springer Verlag, Berlin, Heidelberg, New York.
21. Usman N, Beigelman L & McSwiggen JA (1996). Hammerhead ribozyme engineering. Current Opinion in Structural Biology, 1: 527-533.
22. Cech TR (1993). Structure and mechanisms of the large catalytic RNAs: group I and group II introns and ribonuclease P. In: Gesteland RT & Atkins JF (Editors), The RNA World. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA.
23. Bramlage B, Luzi E & Eckstein F (1998). Designing ribozymes for the inhibition of the gene expression. Trends in Biotechnology, 16: 434-438.
24. Usman N & Blatt LM (2000). Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. Journal of Clinical Investigation, 106: 1197-1202.
25. Dolle RE & Kinsley Jr HN (1999). Comprehensive survey of combinatorial library synthesis: 1998. Journal of Combinatorial Chemistry, 4: 235-282.
26. Janda KD (1994). Tagged versus untagged libraries: methods for the generation and screening of combinatorial chemical libraries. Proceedings of the National Academy of Sciences, USA, 91: 10779-10785.
27. Cho CY, Moran EJ, Cherry SR, Stephans JC, Fodor SPA, Adams CL, Sundaram A, Jacobs JW & Schultz PG (1993). An unnatural biopolymer. Science, 261: 1303-1305.
28. Geysen HM, Meloen RH & Barteling S (1984). Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proceedings of the National Academy of Sciences, USA, 81: 3998-4002.
29. Erb E, Janda KD & Brenner SJ (1994). Recursive deconvolution of combinatorial chemistry. Proceedings of the National Academy of Sciences, USA, 91: 11422-11426.
30. Smith GP (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the viron surface. Science, 228: 1315-1317.
31. Brenner S & Lerner R (1992). Encoded combinatorial chemistry. Proceedings of the National Academy of Sciences, USA, 89: 5381-5383.
32. Osborne SE & Ellington AD (1997). Nucleic acid selection and the challenge of combinatorial chemistry. Chemical Reviews, 97: 349-370.
33. Breaker RR (2000). Making catalytic DNAs. Science, 290: 2095-2096.
34. Latham JA, Johnson R & Toole JJ (1994). The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2′-deoxyuridine. Nucleic Acids Research, 22: 2817-2822.
35. Bock LC, Griffin LC, Latam JA, Vermaas EH & Toole JJ (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355: 564-566.
36. Tarasow TM, Tarasow SL & Eaton B (1997). RNA-catalysed carbon-carbon bond formation. Nature, 389: 54-58.